Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 4 of 4 clinical reviews.
A detailed methodological breakdown of the SURPASS-3 trial comparing tirzepatide to insulin degludec in type 2 diabetes, covering randomization, blinding, estimand framework, comparator choice, and how each design decision shapes clinical interpretation.
Read clinical reviewHealth-economic analyses of the SURPASS-3 trial comparing tirzepatide vs insulin degludec: cost per QALY, payer coverage, list vs net pricing, and relative value for patients with type 2 diabetes.
Read clinical reviewDeep-dive into the SURPASS-3 open-label extension: durability of tirzepatide's A1C and weight benefits vs insulin degludec over 52 additional weeks, safety signals, and long-term clinical implications.
Read clinical reviewA plain-English deep dive into the SURPASS-3 trial comparing tirzepatide vs insulin degludec in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
Read clinical review